Fresenius Medical Care Ag ADR FMS

$22.47 -0.66 (-2.85%)

Valuation

Market cap
12,149,859,000
Revenue TTM
$22,206,670,000
Net income TTM
$1,106,920,000
PE ratio
8.46
Forward PE
10.03
Profit margin
4.98%
Debt to equity
0.56

Trading

Volume
516,341
Avg volume
944,010
Day's range
$22.45 – $22.89
Shares out
537,129,000
Stochastic %K
100%
Beta
0.74
Analysts
Hold
Price target
$21.34

Price

Company profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery o...

Show more

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Industry
Medical Care Facilities
Sector
Healthcare
Phone
49 6172 609 0
Website
https://www.freseniusmedicalcare.com
Address
Else-Kröner-Strasse 1, Bad Homburg, Germany

Latest news

Stocktwits

Yi_YandH Oct 30, 1:55 AM 0 replies
Yi_YandH Oct 30, 1:31 AM
$ICU $FMS The Fresenius newest CRRT beast!
0 replies
Fafa6688 Oct 29, 10:08 PM
$AKBA $DVA $FMS “CMS Policy Support: Empowered by TDAPA (Transitional Drug Additive Payment Adjustment) Subsidies In CMS regulatory documents, Vafseo has been granted eligibility for the TDAPA (Transitional Drug Additive Payment Adjustment). • This policy means that during the transitional period, CMS will provide additional full or partial reimbursement to dialysis centers for Vafseo's drug costs, over and above the standard End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) bundle rate. • This gives dialysis centers greater financial flexibility when purchasing and utilizing new drugs compared to using older medications already locked into the bundle rate. It also allows them to secure more favorable terms and incentives in procurement contracts with pharmaceutical manufacturers. ”
1 replies
Fafa6688 Oct 29, 9:39 PM
$FMS I don’t understand why Fresenius Medical Care (FMS) hasn’t adopted $AKBA’s Vafseo more broadly when it could benefit patients and potentially reduce overall treatment costs for FMS. What is holding them back?
1 replies
Noname2022 Oct 29, 6:39 PM
$CRMD $FMS FMC: “The final rule is largely in line with our expectations” https://freseniusmedicalcare.com/en/investors/news/cms-news-on-end-stage-renal-disease-prospective-payment-system-for-2027/
1 replies
Noname2022 Oct 28, 8:48 PM
$CRMD $AKBA $FMS $DVA https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-end-stage-renal-disease-esrd-prospective-payment-system-final-rule-cms-1846-f
2 replies
Noname2022 Oct 28, 7:29 PM
$CRMD $FMS My take on FMC’s 90% figure: I believe it refers to FFS Medicare patients with catheters >90 days, consistent with their ASN abstract. “with now around 90% of all eligible patients using an antimicrobial catheter lock solution.” https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q1/FME_Q1%202026_Transcript_Final.pdf
0 replies
Yi_YandH Oct 26, 11:09 PM 0 replies